Use of diagnostic testing for managing hepatitis C virus infection

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 2, 2004, Pages 9-18

  Ferreira Gonzalez, Andrea ^b   Shiffman, Mitchell L ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Branched chain DNA assay; Diagnosis; Enzyme linked immunoabsorbent assay; Hepatitis C; Polymerase chain reaction

Indexed keywords

DNA B; HEPATITIS C ANTIBODY; HEPATITIS C VIRUS CORE ANTIGEN; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA;

BRANCHED CHAIN DNA ASSAY; CHRONIC LIVER DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE SEVERITY; ELECTROIMMUNOASSAY; GENOTYPE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; INTERNATIONAL STANDARD UNIT; LINE PROBE ASSAY; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MOLECULAR BIOLOGY; MOLECULAR VIROLOGY TEST; NUCLEIC ACID SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT IMMUNOBLOT ASSAY; REVIEW; SERODIAGNOSIS; SEROLOGY; SEROTYPING; TRANSCRIPTION MEDIATED AMPLIFICATION TEST;

DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 2442626359     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832923     Document Type: Review

References (54)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362
2. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to the major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364
3. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500
4. Gretch DR. Use and interpretation of HCV diagnostic tests in the clinical setting. Clin Liver Dis 1977;1:543-557
5. Zaaijer HL, Cuypers HT, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722-724
6. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO collaborative study group. Vox Sang 1999;76:149-158
7. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-583
8. Fried MW, Hadziannis S. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004;24(suppl 2):47-54
9. Schiff ER, de Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999;19:3-15
10. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26(suppl):43S-47S
11. Kao JH, Lai MY, Hwang YT, et al. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay: a clinicopathologic study and demonstration of the usefulness of a third-generation assay. Dig Dis Sci 1996;41:161-165
12. Barrera J, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-18
13. Fried MW, Draguesku JO, Shindo M, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 1993;38:631-636
14. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1:559-568
15. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus -infected individuals. J Clin Microbiol 2000;38:575-577
16. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87-95
17. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003;7:127-137
18. Alter HJ, Tegtmeier G, Jett B, et al. The use of recombinant immunoblot assay in the interpretation of anti-hepatitis C virus reactivity among prospectively followed patients, implicated donors and random donors. Transfusion 1991;31:771-776
19. Evans C, Tobler L, Polito A, et al. Comparative evaluations of supplemental hepatitis C virus antibody test systems. Transfusion 1992;32:408-414
20. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002;36:211-218
21. Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatits C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol 2002;40:4224-4229
22. Vellion P, Payan C, Picchio G, et al. Comparative evaluation of the total hepatits C virus core antigen, branched-DNA, and Amplicor monitor assays in determining viremia for patients with chronic hepatits C during interferon plus ribavirin combination therapy. J Clin Microbiol 2003;41:3212-3220
23. Sarrazin C. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. J Clin Virol 2002;25(Suppl 3):S23-S29
24. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-1568
25. Zaaijer HL, Cuypers HT, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722-724
26. Nolte FS, Fried MW, Shiffman ML, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001;39:4005-4012
27. Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M, et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods 2001;95:111-119
28. Kleiber J, Walter T, Haberhausen G, et al. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn 2000;2:158-166
29. Kawai S, Yokosuka O, Kanda T, et al. Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay. J Med Virol 1999;58:121-126
30. Hendricks DA, Friesenhahn M, Tanimoto L, et al. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003;41:651-656
31. Hill CS. Molecular diagnostic testing for infectious diseases using TMA technology. Expert Rev Mol Diagn 2001;1:445-455
32. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription mediated amplification in patients with complete virologic response according to polymerase chain reaction-based asays. Hepatology 2000;32:818-823
33. Urdea MS, Horn T, Fultz TJ, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991;24:197-200
34. Pawlotsky JM, Martinot-Peignoux M, Poveda JD, et al. Quantification of hepatitis C RNA in serum by branched chain DNA-based signal amplification assays. J Virol Methods 1999;79:227-235
35. Fang JWS, Chow V, Lau JNY. Virology of hepatitis C virus. Clin Liver Dis 1997;1:493-514
36. Stuyver L, Wyseur A, van Arnhem W, et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypable samples. Virus Res 1995;38:137-157
37. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-2266
38. Zheng X, Pang M, Chan A, et al. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol 2003;28:214-216
39. Anderson JC, Simonetti J, Fisher DG, et al. Comparison of different HCV viral load and genotyping assays. J Clin Virol 2003;28:27-37
40. Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol 1991;72:2105-2112
41. De Cock L, Vranckx R. Serotyping and genotyping of hepatitis C virus in Belgium. Infection 2003;31:92-97
42. Pawlotsky JM, Prescott L, Simmonds P, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Micrbiol 1997;35:1734-1739
43. Pawlotsky JM, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32:654-657
44. Shiffman ML, Ferreria-Gonzalez A, Reddy KR, et al. Comparison of three commercially available assays for HCV RNA utilizing the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003;98:1159-1166
45. Krajden M, Ziermann R, Khan A, et al. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol 2002;40:2903-2907
46. Yu ML, Chuang WL, Dai CY, et al. Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV Version 2.0 test. J Clin Microbiol 2000;38:2933-2939
47. Nguyen T, Sedghi-Vaziri A, Wilkes L, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996;3:75-78
48. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
49. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652
50. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785
51. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders. Gastroenterology 1999;117:1164-1172
52. Lee S. Histological response to interferon alfa-based therapies in hepatitis C. Semin Liver Dis 2004;24(suppl 2):55-60
53. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785
54. Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003;39:106-111